All about retatrutide: the latest weight loss drug

What is retatrutide?

Retatrutide is a new drug currently being developed by the pharmaceutical company Eli Lilly [1].

While most weight loss medications target one or two hormones, retatrutide directly addresses three at once: GLP-1, GIP, and glucagon [2].

These hormones control processes in your body related to hunger, energy expenditure, and fat storage. In other words: retatrutide can help you eat less and boost your metabolism.

Overweight and associated health problems are becoming increasingly common. Retatrutide potentially offers a promising new way to effectively lose weight [1].

In short: Retatrutide acts as a three-in-one booster for your metabolism: less hunger, increased energy burning, and better regulation of blood sugar and fat storage.

How does retatrutide work?

What makes retatrutide so unique is that it simultaneously acts on three hormones:

1. GLP-1: Suppresses appetite and slows gastric emptying, making you feel full faster.
2. GIP: Supports insulin production and influences how your body stores fat.
3. Glucagon: Converts stored fat into energy, causing your body to burn more.

Perhaps you recognize this scenario: you try to eat less and move more, but the number on the scale doesn't change. This is often because your body starts conserving energy as a survival mechanism. 

Retatrutide appears to disrupt this mechanism by simultaneously reducing hunger and increasing metabolism.

‍In short: Retatrutide helps your body manage energy more intelligently, potentially leading to more effective weight loss.

What is the difference compared to other weight loss medications?

Most existing weight loss medications target one or two hormones. 

Semaglutide (Ozempic, Wegovy) only affects GLP-1, while tirzepatide (Mounjaro) addresses both GLP-1 and GIP.

Retatrutide goes a step further by also activating the glucagon receptor. This hormone helps your body burn stored fats and use them as energy. 

Thanks to this additional mechanism, retatrutide can be more effective against stubborn fat, such as visceral fat, and thus potentially lead to greater weight loss than previous medications.

In short: Retatrutide is the first weight loss medication to leverage three hormones simultaneously. As a result, it not only reduces hunger but also enhances your body's ability to burn fat.

What promising results are we seeing in current studies?

The initial clinical studies show impressive results. 

In a comprehensive Phase 2 study, published in The New England Journal of Medicine, participants lost an average of over 24% of their body weight after 48 weeks [3].

Even more recent data from the Phase 3 TRIUMPH-4 trial shows that people on the highest dosage lost an average of 28.7% of their body weight (approximately 32 kilograms) after 68 weeks [4]. 

The effect on the liver is also remarkable: in patients with fatty liver disease, harmful fat decreased by more than 80%, and most participants had a virtually healthy liver again afterward [5].

But the benefits of retatrutide extend beyond weight loss and visceral fat:

• Osteoarthritis and joint pain: the same TRIUMPH-4 study (December 2025) shows that patients with knee osteoarthritis reported a 60% reduction in their pain [4].
• Type 2 Diabetes: In March 2026, Eli Lilly published the results of the TRANSCEND-T2D-1 trial. Patients lost an average of nearly 17% of their body weight in 40 weeks, and their blood sugar levels (HbA1c) decreased by 2.0% [6]. This makes retatrutide particularly interesting for individuals with both overweight and diabetes.

In short: Recent studies show that retatrutide not only aids in significant weight loss (up to nearly 29%) but also drastically reduces dangerous visceral fat, alleviates joint pain, and improves blood sugar regulation.

How is retatrutide currently being tested?

Before a drug like retatrutide can be approved for market, it must undergo rigorous clinical trials to prove it is both effective and safe. 

Retatrutide is currently in its final Phase 3 studies.

A key component of this is the TRIUMPH-Outcomes study [7]. This large-scale, global study investigates whether retatrutide, in addition to weight loss, can also help prevent heart and kidney complications in individuals with overweight. 

This information is important for doctors: it shows who benefits most from the treatment and what potential long-term effects and side effects (such as gastrointestinal issues) may occur.

In short: Retatrutide is currently being tested on thousands of subjects worldwide, investigating not only safe and effective weight loss but also its potential protective effects on the heart and kidneys.

When will retatrutide be available?

As the Phase 3 studies are still ongoing, retatrutide has not yet been officially approved by health authorities such as the US FDA or the European EMA. 

This means the drug is not yet available through pharmacies or regular doctors. It is expected to be prescribable only by late 2026 or in 2027, once the studies are fully completed and long-term safety has been confirmed.

Caution: Unregulated 'peptides' are offered online. The safety, purity, and effectiveness of these substances are uncertain and may pose health risks.

In short: Retatrutide is not yet available, and purchasing illegal online products is dangerous and irresponsible. Only after the completion of Phase 3 studies will it be clear when the drug can be safely prescribed.

Conclusion

Thanks to its unique triple action, retatrutide promises to be a significant step forward in weight loss and metabolic health. The initial research results are promising.

We still need to be patient. The long-term safety and effects must first be fully confirmed in the concluding Phase 3 studies before retatrutide will be available in pharmacies.

But you don't have to wait to reach your target weight. With current medical options, you can start your weight loss journey today.

Curious which personalized treatment plan best suits your body and goals? Fill out the short online questionnaire and find out immediately.

‍Start today